The State of U.S. Charity Care: Solutions to Improve the Patient Experience and Achieve More Equitable Health Outcomes
WASHINGTON, DC / ACCESSWIRE / October 22, 2024 / Today, the Health Equity Collaborative (HEC), a diverse community comprised of dozens of national, public health, patient advocacy, and multicultural organizations committed to supporting equity and combating disparities experienced by underserved communities, published a new research paper that reviews the history and current state of charity care in the United States and outlines several policy reforms to ensure underserved populations can receive the care they need.
The paper expands on policy priorities HEC outlined in their Health Equity Guidelines Letter to the 118th Congress and President Biden earlier this year.
“The charity care system is a patchwork quilt of varying standards and eligibility requirements, leaving many vulnerable communities without access to essential healthcare. We need a more equitable and sustainable model that prioritizes patient needs, regardless of their ability to pay,” said Amy Hinojosa, President and CEO of MANA, A National Latina Organization.
The paper identifies several opportunities for policymakers to reform the current charity care system:
Require Additional Transparency Over Hospital Billing, Charity Care Programs & Medical Debt Collection Practices
Enforce Transparency Requirements to Address Hospital Noncompliance
Create a National Standard for Charity Care
Reform the 340B Drug Pricing Program
In the months ahead, the Health Equity Collaborative will publish additional research and continue to lead discussions with key healthcare stakeholders about realizing progress for diverse communities.
Read the full paper here.
To learn more about the Health Equity Collaborative, please visit our website at https://healthequitycollaborative.org.
For media inquiries, please contact info@healthequitycollaborative.org.
Contact Information
Amy Hinojosa
info@healthequitycollaborative.org
SOURCE: Health Equity Collaborative
View the original press release on newswire.com.
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…
